Interventional Study on Smoking Reduction in Psychiatry

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGCS-CCOMS

About this trial

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected.

The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.

Eligibility criteria

Qualifiers

Regular smokers (at least one cigarette per day)

Followed in psychiatric ambulatory care at one of the participating sectors' CMPs

Adults (18 years or older)

Covered by the statuary health insurance

Disqualifiers

Users under guardianship or legal protection,

Psychological state incompatible with completing the questionnaire,

Persons with no command or understanding of the French language

Trial design

Treatments tested in this trial

  • TABAPSY
  • Usual Care

Treatment groups

6,500 Participants
are divided into 2 treatment groups

Sponsors and collaborators

GCS-CCOMS

Lead sponsor

INSERM ECEVE 1123

Collaborator